The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Levin O.S.
Russian Medical Academy of Continuous Professional Education
Voznyuk I.A.
Pavlov First Saint Petersburg State Medical University;
Immanuel Kant Baltic Federal University
Illarioshkin S.N.
Research Center of Neurology
Bogolepova A.N.
Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies
Vasenina E.E.
Russian Gerontological Scientific and Clinical Center of Pirogov Russian National Research Medical University
Gavrilova S.I.
Mental Health Research Centre
Dokukina T.V.
Republican Scientific and Practical Center of Mental Health
Lobzin V.Y.
Kirov Military Medical Academy;
Mechnikov North-Western State Medical University
Mkhitaryan E.A.
Research Center of Neurology
Khatkova S.E.
National Medical Research Center «Treatment and Rehabilitation Center»
Yakushin M.A.
Moscow Regional Research and Clinical Institute;
Semashko National Research Institute of Public Health
Yanishevsky S.N.
Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation
Cognitive impairment and tactics of using the drug Cerebrolysin. Resolution of the International Council of Experts (May 12, 2023)
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(9): 121‑130
Views: 5458
Downloaded: 294
To cite this article:
Levin OS, Voznyuk IA, Illarioshkin SN, et al. . Cognitive impairment and tactics of using the drug Cerebrolysin. Resolution of the International Council of Experts (May 12, 2023). S.S. Korsakov Journal of Neurology and Psychiatry.
2023;123(9):121‑130. (In Russ.)
https://doi.org/10.17116/jnevro2023123091121
The aging of the population and the associated increase in the share of cognitive impairments in the structure of a wide range of diseases are a serious challenge for modern healthcare. Difficulties in the treatment of cognitive disorders are determined by many factors, including the age of patients, comorbidity, forced polypragmasia and the adequacy of the dosage of drugs that restore cognitive activity. The experts discussed information about the therapeutic potential of the drug Cerebrolysin in the treatment of cognitive disorders of various origins, stated significant experience of its effective and safe use in many clinical studies in mild and moderate forms of dementia. At the same time, there was a lack of consistent and systematic data on the dosage regimen, frequency, and duration of use of the drug in different forms of cognitive impairment and the degree of their severity. The aim of the international council of experts was to determine the optimal dosage regimens of the drug Cerebrolysin in patients with various etiologies and severity of cognitive impairment. The result of the work was the approval of a unified scheme for the use of the drug Cerebrolysin, considering the severity of the disease and its duration.
Authors:
Levin O.S.
Russian Medical Academy of Continuous Professional Education
Voznyuk I.A.
Pavlov First Saint Petersburg State Medical University;
Immanuel Kant Baltic Federal University
Illarioshkin S.N.
Research Center of Neurology
Bogolepova A.N.
Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies
Vasenina E.E.
Russian Gerontological Scientific and Clinical Center of Pirogov Russian National Research Medical University
Gavrilova S.I.
Mental Health Research Centre
Dokukina T.V.
Republican Scientific and Practical Center of Mental Health
Lobzin V.Y.
Kirov Military Medical Academy;
Mechnikov North-Western State Medical University
Mkhitaryan E.A.
Research Center of Neurology
Khatkova S.E.
National Medical Research Center «Treatment and Rehabilitation Center»
Yakushin M.A.
Moscow Regional Research and Clinical Institute;
Semashko National Research Institute of Public Health
Yanishevsky S.N.
Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation
Received:
15.08.2023
Accepted:
15.08.2023
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.